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It is uncertain how best to screen pregnant women for the presence of fetal Down’s
syndrome: to perform first-trimester screening, to perform second-trimester screen-




Women with singleton pregnancies underwent first-trimester combined screening
(measurement of nuchal translucency, pregnancy-associated plasma protein A [PAPP-A],
and the free beta subunit of human chorionic gonadotropin at 10 weeks 3 days through
13 weeks 6 days of gestation) and second-trimester quadruple screening (measure-
ment of alpha-fetoprotein, total human chorionic gonadotropin, unconjugated estriol,
and inhibin A at 15 through 18 weeks of gestation). We compared the results of step-
wise sequential screening (risk results provided after each test), fully integrated screen-
ing (single risk result provided), and serum integrated screening (identical to fully in-




First-trimester screening was performed in 38,167 patients; 117 had a fetus with Down’s
syndrome. At a 5 percent false positive rate, the rates of detection of Down’s syndrome
were as follows: with first-trimester combined screening, 87 percent, 85 percent, and
82 percent for measurements performed at 11, 12, and 13 weeks, respectively; with
second-trimester quadruple screening, 81 percent; with stepwise sequential screening,
95 percent; with serum integrated screening, 88 percent; and with fully integrated
screening with first-trimester measurements performed at 11 weeks, 96 percent.
Paired comparisons found significant differences between the tests, except for the




First-trimester combined screening at 11 weeks of gestation is better than second-
trimester quadruple screening but at 13 weeks has results similar to second-trimester
quadruple screening. Both stepwise sequential screening and fully integrated screen-
ing have high rates of detection of Down’s syndrome, with low false positive rates.
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Down’s syndrome that includes the use of
ultrasonography to assess nuchal translu-
cency has become widespread since its introduction




The largest U.S. study of first-trimester screening
to date, involving 8514 pregnancies, reported a 79





 Second-trimester screening remains the most
common approach to assessing the risk of Down’s




 When inhibin A is
included in second-trimester quadruple screening,
the estimated detection rate for Down’s syndrome




However, little information is available on the com-
parative performance of these first- and second-
trimester approaches. More complex options for
risk assessment have also become available, includ-
ing sequential screening (performance of screen-
ing tests at different times during pregnancy, with
the results provided to the patient after each test)
and integrated screening (performance of screen-
ing tests at different times during pregnancy, with
a single result provided to the patient only after all




Accurate comparison of the performance of dif-
ferent screening tests conducted at different times
during pregnancy remains complex because of the
bias that can arise from spontaneous pregnancy
losses that may occur between the first-trimester
and the second-trimester screenings. We conducted
the First- and Second-Trimester Evaluation of Risk
(FASTER) Trial with the goal of providing direct
comparative data on currently available screening





This study was conducted at 15 U.S. centers from
October 1999 to December 2002. Institutional re-
view board approval was obtained, and the partici-
pants gave written informed consent. The inclusion
criteria were a maternal age of 16 years or older,
pregnancy with a singleton live fetus, and a fetal
crown–rump length of 36 to 79 mm (consistent
with a gestational age of 10 weeks 3 days through




 Women were ex-
cluded from the study if they had undergone prior
measurement of nuchal translucency or if anen-
cephaly was diagnosed in the fetus. Patients whose
fetuses had septated cystic hygroma were followed
separately without contributing serum samples.
The first-trimester risk was calculated from mea-
surements of nuchal translucency and two serum
markers, pregnancy-associated plasma protein A





hCG), together with maternal
age. The patients returned at 15 to 18 weeks of ges-
tation for second-trimester screening. At this time,
a second-trimester risk was calculated from mea-
surements of serum alpha-fetoprotein, total human
chorionic gonadotropin (hCG), unconjugated es-
triol, and inhibin A, together with maternal age.
Ultrasonography to assess nuchal translucency
was performed according to a standardized proto-





imum of 20 minutes was reserved for the assess-
ment, and transvaginal ultrasonography was used
if necessary. The patient could return for a second
evaluation if the initial attempt failed. All images
were scored by a single reviewer at the main study
center, and feedback was provided to the ultra-
sonographers. A random selection of 10 percent of
images underwent additional review by an indepen-
dent ultrasound quality-assurance committee. Me-
dian nuchal-translucency measurements and their
standard deviations were monitored according to
ultrasonographer and study site. Drift in these val-





Measurements of biochemical markers were con-
verted into multiples of the median (MoM) for ges-
tational age, adjusted for maternal weight and race
or ethnicity. Nuchal-translucency MoM values were
center-specific, and the mean of three measure-
ments was used for calculation of risk. The risk of
Down’s syndrome was estimated by multiplying the
maternal age-specific odds of the live birth of an in-




 by the likeli-
hood ratio obtained from the overlapping gaussian
distributions of affected and unaffected pregnan-










 The distributions of nuchal-translucency
measurements were based on all pregnancies, in-
cluding those in which cystic hygromas were found.
The patients were provided with two separate esti-
mates of the risk of Down’s syndrome, with cutoff
f
methods
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points chosen at the start of the trial; a positive re-
sult from first-trimester screening was defined as a
risk at the end of pregnancy (40 weeks) of 1 in 150,
and a positive result from second-trimester screen-
ing was defined as a risk at the end of pregnancy of
1 in 300. Because second-trimester screening was
considered the standard of care, the risk cutoff
point was chosen so that the rate of positive screen-
ing results was similar to that of current screening
practice — that is, a rate of 5 percent, given the age
distribution of pregnancies in the United States.
The first-trimester risk cutoff point was chosen to
yield a lower rate of positive screening results (2 to
3 percent) in order to ensure that the overall rate for
the study population would not be excessive. The re-
sults were provided to the patients after all screening
tests were complete, and patients with positive re-
sults from either first-trimester or second-trimester
screening were offered formal genetic counseling




The following screening tests for fetal Down’s syn-
drome were evaluated: measurement of first-tri-
mester nuchal translucency alone; first-trimester





measured); first-trimester combined screening





ond-trimester quadruple screening (alpha-fetopro-
tein, total hCG, unconjugated estriol, and inhibin
A); independent sequential screening (the results
of combined screening were provided to the pa-
tient in the first trimester, and the results of qua-
druple screening in the second trimester, with both
risks calculated independently); stepwise sequen-
tial screening (the results of combined screening
were provided in the first trimester, and the results
of quadruple screening in the second trimester; the
risk in the second trimester was calculated with in-
clusion of the marker levels measured in the first
trimester); serum integrated screening (PAPP-A was
measured in the first trimester, and the results were
not provided to the patient; quadruple markers were
measured in the second trimester, and the risk in
the second trimester was calculated with inclusion
of the marker levels measured in the first trimester);
and fully integrated screening (identical to serum
integrated screening with the addition of first-tri-
mester measurement of nuchal translucency). For





Research coordinators at each clinical site recorded
information on patients by using a computerized
tracking system to maximize the amount of data
obtained. Copies of fetal and pediatric medical rec-
ords were submitted for review by a single pediatric
geneticist in all cases in which a possible fetal or
neonatal medical problem was suspected, in all
cases with a positive screening-test result but with-
out karyotype results, and in a 10 percent random
sample of all other cases in enrolled patients. Fetal
chromosome status was determined by amniocen-
tesis; by sampling neonatal cord blood in cases with
a positive screening-test result in which the mother
declined amniocentesis; or by tissue sampling in
cases of spontaneous pregnancy loss, pregnancy
termination, or stillbirth.
Completeness of ascertainment was assessed by
calculating the expected number of cases of Down’s
syndrome from the maternal age distribution of the





 On the basis of these data, 112 cases of
Down’s syndrome were expected in the second tri-
mester; we identified 117 cases, suggesting that all




Screening performance was based on the maternal
age-specific risk of having an affected live-born
child, corrected to early mid-trimester to allow for





 and applied to the U.S. standard




 MoM values for
each pregnancy were calculated by dividing the ob-
served marker concentration by the median value for
unaffected pregnancies with the same fetal crown–
rump length. The first trimester was not treated as
a single time period, because MoM values of the
markers in affected pregnancies change linearly
with gestational age. Confidence intervals for the es-
timates of screening performance of the combined,
quadruple, fully integrated, serum integrated, and
stepwise sequential testing strategies were derived
by bootstrapping with 1000 Down’s syndrome data-
set replications. These confidence intervals give the
range of values within which the true screening
performances are likely to lie. To compare screen-
ing performances of different strategies, the differ-
ence between pairs of tests was determined for each
dataset replication and the 95 percent confidence
intervals of these differences were calculated.
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An independent replication of the data analysis
was performed by the Foundation for Blood Re-
search, Scarborough, Maine, and the results were
reported to the data-monitoring committee, which
was independent of the FASTER Trial consortium.
These results were consistent with those of the pri-
mary analysis.
A total of 42,367 patients were approached for en-
rollment (Fig. 1). The demographic characteristics
of the 38,033 patients enrolled are summarized in
Table 1. Data on pregnancy and pediatric outcomes
were obtained in 36,837 cases (97 percent). One
hundred two approved ultrasonographers per-
formed all nuchal-translucency evaluations. The ul-
trasonographer failed to obtain an adequate nuchal-
translucency image in 1727 cases (4.5 percent),
and in a further 974 cases (2.6 percent) the images
were rejected at central review. Adequate nuchal-
translucency measurements were therefore ob-
tained in 35,332 cases (92.9 percent). Complete
first- and second-trimester screening data were
available for 33,459 unaffected pregnancies and 87
pregnancies affected by Down’s syndrome. There
were 117 cases of Down’s syndrome in the popula-
tion of 38,167 patients (38,033 enrolled patients
plus 134 patients whose fetuses had cystic hygro-
mas). Of the 117 cases of Down’s syndrome, 25
were in the cystic-hygroma subgroup and 92 oc-
curred among the 38,033 pregnancies described in
this report.
Table 2 summarizes the performance of first-
and second-trimester screening, by counting the
number of detected and false positive cases above
the risk cutoff levels used. Table 3 presents the me-
dian MoM values in pregnancies affected by Down’s
results
 
Figure 1. Recruitment of Subjects in the FASTER Trial.
 
NT denotes nuchal translucency, and DS Down’s syndrome.
38,189 Eligible
42,367 Approached






from 37,843 (92 with DS)
Measured NT in 36,306
(92 with DS)
Second-trimester serum obtained
from 35,236 (87 with DS)
Complete first-trimester data
for 36,120 (92 with DS)
Complete first- and second-trimester
data for 33,546 (87 with DS)
4178 Ineligible or refused
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syndrome for individual markers at each week dur-
ing the first trimester and the detection rates for
each marker used alone. The median MoM values
in affected pregnancies are not constant from 11
through 13 weeks of gestation, so that the perfor-
mance of tests that include measurement of nuchal
translucency and PAPP-A declines, and the perfor-





improves, over this time period.
The second-trimester median MoM values for
markers in affected pregnancies were 0.74 for alpha-
fetoprotein (95 percent confidence interval, 0.67 to
0.82), 1.79 for hCG (95 percent confidence inter-
val, 1.59 to 2.01), 0.61 for unconjugated estriol (95
percent confidence interval, 0.55 to 0.67), and 1.98
for inhibin A (95 percent confidence interval, 1.74
to 2.26). The observed median MoM value of 0.61
for unconjugated estriol was substantially lower




In a meta-analysis of 733 pregnancies affected by
Down’s syndrome, the median MoM value for un-
conjugated estriol was 0.72 (95 percent confidence




 The effect of this unexpect-
ed finding in our study would be improved rates of
detection of Down’s syndrome, at a 5 percent false
positive rate, of 86 percent (instead of 81 percent)
for quadruple screening and 78 percent (instead of
69 percent) for triple screening. The median MoM
value of 0.61 for unconjugated estriol is likely to be
an outlying low result that would tend to produce
an overestimation of second-trimester screening
performance, since the 95 percent confidence in-
tervals of our observed values and the meta-analy-
sis values do not overlap, whereas our other results
are all consistent with published values. Our sub-
sequent results are therefore based on the pooled
median MoM of 0.72 for unconjugated estriol ob-




Table 4 shows the estimated performance of a
 
* The mean (±SD) maternal age at the expected date of delivery was 30.1±5.8 years.
 
† Race or ethnic group was self-reported.
 











Maternal age at expected date
of delivery*
<35 Yr 29,834 28 78.4
≥35 Yr 8,199 64 21.6
Maternal race or ethnic group†
White 25,459 65 66.9
Hispanic 8,607 17 22.6
Black 2,031 5 5.3
Asian 1,556 4 4.1
Other 380 1 1.0
Gestational age of fetus at first-
trimester screening
10 wk 3 days to 10 wk 6 days 1,345 0 3.5
11 wk 0 days to 11 wk 6 days 8,583 19 22.6
12 wk 0 days to 12 wk 6 days  17,052 44 44.8  
13 wk 0 days to 13 wk 6 days 11,053 29 29.1
 
* The detection rate is subject to bias, because an unknown proportion of fetuses with hygroma might have been sponta-
neously aborted before the second trimester, when most cases of Down’s syndrome were ascertained.
† The detection rate is based on a positive result from either the first-trimester combined screening at a risk cutoff of 1 in 




Table 2. Directly Observed Performance Characteristics of First- and Second-Trimester Screening Tests for Down’s Syndrome.
Screening Test Risk Cutoff Detection Rate* False Positive Rate
 
percent (no. positive/total no.) percent
 
First-trimester combined screening
Hygroma not included 1:150 77 (71/92) 3.2 
Hygroma included 1:150 82 (96/117) 3.2 
First-trimester combined screening
Hygroma not included 1:300 82 (75/92) 5.6 
Hygroma included 1:300 86 (100/117) 5.6 
Second-trimester quadruple screening 1:300 85 (74/87) 8.5 
Sequential screening in both trimesters† 1:150 for 1st trimester
1:300 for 2nd trimester
94 (82/87) 11
Copyright © 2005 Massachusetts Medical Society. All rights reserved. 
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variety of screening approaches, applied to the
1999 U.S. distribution of maternal ages (mean age,





 First-trimester serum screening and nuchal-
translucency measurement perform similarly, but
the combination of both is superior for detecting
Down’s syndrome at 11 to 13 weeks of gestation.
Serum integrated screening performs similarly to
first-trimester combined screening yet does not
require nuchal-translucency measurement. Fully
integrated screening (including measurement of
nuchal translucency) yields the highest detection
rates with the lowest false positive rates as compared
with other forms of screening. Quadruple screen-
ing performs better than triple screening (measure-
ment of alpha-fetoprotein, hCG, and unconjugat-
ed estriol), with both lower false positive rates and
higher detection rates. The detection rates at vari-
ous false positive rates and the false positive rates at
various detection rates are summarized in Table 4.
To compare the performance of different screen-
ing tests, it is not appropriate to rely on the 95 per-
cent confidence intervals surrounding the point es-
timates of performance of the main screening tests,
as shown in Table 4. Therefore, the performance of
different screening tests was compared on the basis
of many samplings from the study population.
These comparisons showed that, at false positive
rates of 1 percent or 5 percent, the detection rates
were significantly different for the various testing
strategies, except for the serum integrated and
combined-screening tests, for which the detection
rates were not significantly different (Table 5).
Subgroup analyses were performed of data
from women 35 years of age or older and from
those younger than 35 years. For women 35 or old-
er, first-trimester combined screening had a detec-
tion rate of 95 percent at a false positive rate of 22
percent, as compared with a detection rate of 92
percent at a false positive rate of 13 percent for sec-
ond-trimester quadruple screening and a detection
rate of 91 percent at a false positive rate of 2.0 per-
cent for integrated screening (with first-trimester
markers measured at 11 weeks). For women under
35, first-trimester combined screening had a de-
tection rate of 75 percent at a 5.0 percent false pos-
itive rate, as compared with a detection rate of 77
percent at a 2.3 percent false positive rate for sec-
ond-trimester quadruple screening and a detection
rate of 77 percent at a 0.4 percent false positive rate
for integrated screening.
Another option is stepwise sequential screen-
 




hCG the free beta subunit of hu-
man chorionic gonadotropin. 
† The estimated MoM values were derived from regression of the value of each marker against gestational age.
 
‡ The detection rates were estimated without the use of maternal age.
 
Table 3. Multiple of the Median (MoM) Values for First-Trimester Levels of Markers in Pregnancies Affected by Down’s 
Syndrome and Estimated Detection Rates for a 5 Percent False Positive Rate.*







Estimated† 2.13 1.91 1.71 
Observed (95% CI) 2.14 (1.58–2.91) 2.26 (1.80–2.84) 1.43 (1.06–1.95)
PAPP-A
Estimated† 0.42 0.47 0.53 






Estimated† 1.89 2.05 2.23 
Observed (95% CI) 2.08 (1.16–3.70) 1.79 (1.21–2.66) 2.42 (1.52–3.85)
 
estimated detection rate (percent)
 
‡
Nuchal translucency 63 60 55 





hCG 22 25 29 
Copyright © 2005 Massachusetts Medical Society. All rights reserved. 
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ing, in which patients undergo first-trimester com-
bined screening with the results provided imme-
diately and those with positive tests are offered
chorionic villus sampling. Patients with negative
tests return at 15 weeks so that the quadruple
markers can be measured, and a new risk estimate
is provided that combines the results of measure-
ment of the first-trimester and the second-trimes-
ter markers. Setting a 2.5 percent false positive rate
for each screening component in this model re-
sults in an estimated detection rate of Down’s syn-
drome of 95 percent (95 percent confidence inter-
val, 91 to 97 percent), at an overall false positive
rate of 4.9 percent. At the same 95 percent detec-
tion rate, the false positive rate for fully integrated
screening was 4.0 percent (the 95 percent confi-
dence interval for the difference between stepwise
sequential and fully integrated screening is 0.1 to
1.3 percent).
The FASTER Trial was designed to compare, in a
single population, first-trimester screening for
Down’s syndrome with second-trimester screen-
ing (the current standard of care) and with screen-
ing in both trimesters. Our results demonstrate
that first-trimester screening for Down’s syndrome
is highly effective, but combinations of measure-
ments of markers from both the first and the sec-
ond trimesters yield higher detection rates and
lower false positive rates.
We found that using both nuchal translucency
and serum markers in the first trimester is more ef-
fective in screening for Down’s syndrome than us-





hCG determinations to measure-
ment of nuchal translucency increases the detec-
tion rate of Down’s syndrome from 70 percent to
discussion
 
* A 95 percent confidence interval that does not include zero suggests a significant difference between the results of the two screening tests. 
Significant differences were found for all pairs of tests in the table, except for the serum integrated test versus the combined test. The first-
trimester markers for the combined and fully integrated tests were measured at 11 weeks of gestation, except where otherwise stated. CI 
denotes confidence interval.
† The combined test in the first trimester consists of measurement of nuchal translucency, pregnancy-associated plasma protein A (PAPP-A), 










§ The quadruple test consists of measurement of alpha-fetoprotein, hCG, unconjugated estriol, and inhibin A in the second trimester.
¶The serum integrated test consists of measurement of PAPP-A in the first trimester and alpha-fetoprotein, hCG, unconjugated estriol, and in-
hibin A in the second trimester. The fully integrated test consists of measurement of nuchal translucency and PAPP-A in the first trimester and 
 
alpha-fetoprotein, hCG, unconjugated estriol, and inhibin A in the second trimester.
 
Table 5. Differences in False Positive Rates for a Given Detection Rate, and Differences in Detection Rates for a Given False Positive Rate 
for Specified Pairs of Screening Tests.*
Screening Test Percent Detection Rate Percent False Positive Rate
 
75 85 95 1 5
 
percentage points of difference
between false positive rates (95% CI)
percentage points of difference 
between detection rates (95% CI)
 
Combined — 11 vs. 12 wk† ¡0.2 (¡0.6 to 0.0) ¡1.0 (¡1.9 to ¡0.3) ¡3.7 (¡5.4 to ¡2.3) 1.5 (0.1 to 2.6) 1.8 (1.1 to 2.5)
Combined — 11 vs. 13 wk† ¡1.1 (¡2.1 to ¡0.4) ¡3.1 (¡4.9 to ¡1.6) ¡8.1 (¡12 to ¡5.2) 6.1 (3.8 to 8.5) 4.9 (3.3 to 6.5)
Combined — 12 vs. 13 wk† ¡0.8 (¡1.5 to ¡0.4) ¡2.1 (¡3.1 to ¡1.3) ¡4.4 (¡6.2 to ¡2.7) 4.6 (3.6 to 6.0) 3.1 (2.2 to 4.0)
Nuchal translucency alone vs. combined† ¡6.9 (¡10 to ¡2.6) ¡16 (¡23 to ¡9.1) ¡38 (¡49 to ¡29) 19 (14 to 28) 17 (12 to 24)
Serum only vs. combined†‡ ¡5.9 (¡8.7 to ¡3.2) ¡12 (¡16 to ¡6.9) ¡24 (¡33 to ¡15) 23 (17 to 30) 17 (11 to 21)
Combined† vs. quadruple§ ¡1.9 (¡6.0 to ¡0.6) ¡3.5 (¡12 to ¡0.3) ¡4.4 (¡22 to 6.9) 13 (5.0 to 29) 6.5 (0.0 to 18)
Serum integrated vs. combined†¶ 0.0 (¡0.8 to 1.6) ¡0.2 (¡2.6 to 3.8) ¡2.7 (¡12 to 9.8) 0.2 (¡12 to 7.2) 0.5 (¡7.4 to 5.8)
Fully integrated vs. combined†¶ ¡1.0 (¡2.0 to ¡0.4) ¡3.1 (¡5.7 to ¡1.4) ¡14 (¡22 to ¡6.4) 15 (3.3 to 19) 8.6 (4.5 to 12)
Quadruple vs. triple ¡3.9 (¡7.0 to ¡2.3) ¡6.3 (¡12 to ¡3.3) ¡9.5 (¡19 to ¡3.1) 16 (7.7 to 22) 11 (5.8 to 17)
Serum integrated vs. quadruple ¡1.9 (¡4.8 to ¡1.3) ¡3.7 (¡8.7 to ¡2.3) ¡7.1 (¡14 to ¡3.6) 13 (10 to 19) 7.0 (4.6 to 12)
Fully integrated vs. quadruple ¡3.0 (¡6.8 to ¡1.9) ¡6.7 (¡14.2 to ¡4.1) ¡18 (¡34 to ¡11) 28 (23 to 38) 15 (11 to 24)
Fully integrated vs. serum integrated ¡1.0 (¡2.3 to ¡0.5) ¡2.9 (¡6.3 to ¡1.6) ¡11 (¡20 to ¡6.2) 15 (10 to 22) 8.1 (4.9 to 14)
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87 percent, at a 5 percent false positive rate (Table 4).
The differences observed between combined screen-
ing and measurement of either nuchal translucency
or serum markers alone are clinically significant
and support the use of first-trimester combined
screening for risk assessment. The only exception
may be in the case of multiple gestations (which
were excluded from the present study), in which
serum markers are difficult to interpret and nuchal-
translucency measurements may allow for fetus-
specific risk calculation.





hCG appeared to improve between
11 and 13 weeks, the effectiveness of screening by
measurement of nuchal translucency or PAPP-A
declined over this interval, so that screening at 11
weeks resulted in better detection rates overall.
Other screening programs that use first-trimester
markers, such as integrated or sequential screen-
ing, will also be subject to degradation in perfor-
mance if the first-trimester component is delayed
until 13 weeks. Estimates of risk based on gesta-
tional age-specific measurements will be more
accurate than estimates based on measurements
taken during the period from 11 through 13 weeks
as a whole.
Ultrasonography for the measurement of nuchal
translucency can be a difficult technique to perform
consistently well, as evidenced by the 7 percent rate
of failed or suboptimal imaging in our study. A re-
cent U.S. study suggested a rate of failure to obtain
an image of only 0.5 percent, but no data were pro-




 However, the detection rate
of Down’s syndrome by measurement of nuchal
translucency appeared lower than in the present




This suggests that quality assurance, as performed
by us, may contribute to improved screening per-
formance.
Second-trimester quadruple screening had a
higher false positive rate than first-trimester com-
bined screening performed at 11 or 12 weeks. The
estimated performance based on week-specific
measurements indicated an advantage of com-
bined screening over quadruple screening if the
first-trimester measurements are obtained at 11
weeks, but not if they are obtained later.
In our study, the first-trimester results were not
released until the completion of second-trimester
screening so as to allow an unbiased comparison
of the two approaches. Since fetuses with septated
cystic hygroma are at particularly high risk for fetal
aneuploidy, patients with this finding were imme-
diately informed and offered chorionic villus sam-





 Thus, our estimates of screening
performance apply only to pregnancies without
cystic hygromas.
Measurement of a combination of markers in
both the first and the second trimesters provides
the best screening performance. We studied the
performance of two types of integrated screening
(involving measurement of markers at different ges-
tational ages, but provision of a single result after




: the fully integrated model,
which incorporates first-trimester nuchal-translu-
cency measurements, and the serum integrated
model, which does not. A single prospective nested
case–control study from Europe found Down’s
syndrome detection rates of 94 percent for fully
integrated screening and 87 percent for serum in-





 In the current study, fully integrated screen-
ing performed significantly better than either first-
trimester combined screening or second-trimester
quadruple screening alone. Serum integrated
screening performed similarly to first-trimester
combined screening and may be a useful alternative
in situations in which staff appropriately trained in
assessing nuchal translucency are not available.
The differences between screening tests were less
apparent if the false positive rate was set at 5 percent
(as has been commonly adopted) rather than 1 per-
cent, because the detection rates of all the tests are
relatively high.
A major disadvantage of integrated screening is
that it precludes the performance of chorionic
villus sampling for early definitive diagnosis. With
independent sequential screening, first-trimester
combined-screening results are provided immedi-
ately, and women with positive results may choose
to undergo chorionic villus sampling. Women with
negative results return for quadruple screening,
the results of which are interpreted without refer-
ence to the first-trimester results. Our results indi-
cate a high false positive rate (11 percent, for a 94
percent detection rate) and reduced accuracy with
such a strategy and thus suggest that it should not
be used.
Stepwise sequential screening, in contrast, keeps
the false positive rate low and provides early results
to women with a positive test, but it combines the
results of both the first-trimester and the second-
trimester measurements into a final second-trimes-
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ter risk assessment. With first-trimester combined
screening at 11 weeks, and a false positive rate of
each component set at 2.5 percent, stepwise se-
quential screening resulted in a high detection rate
of Down’s syndrome, similar to that obtained by
fully integrated screening, although with a slightly
higher false positive rate. The sequential approach
described here is simply one example of sequential
testing. (Setting different false positive rates would
result in different yields.) Further research is needed
to determine the most effective method of sequen-
tial screening and to compare it with other screen-
ing programs.
In conclusion, when there is appropriate quality
control for measurement of nuchal translucency,
first-trimester combined screening is a powerful
tool for the detection of Down’s syndrome. Step-
wise sequential screening and fully integrated
screening are both associated with high detection
rates and acceptable false positive rates; the advan-
tage of earlier diagnosis associated with sequential
screening must be weighed against the lower false
positive rate obtained with integrated screening.
Consideration of the costs associated with differ-
ent strategies and of patient preferences will help
guide the choice between these approaches.
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